Literature DB >> 16146805

Cyclins and CDKS in development and cancer: lessons from genetically modified mice.

David Santamaria1, Sagrario Ortega.   

Abstract

From yeast to humans, cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the finding that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Recent information from gene-targeted mouse models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. Unexpectedly, most of the canonical Cdk-cyclin complexes have turned out to be dispensable for cell proliferation due to a high level of functional redundancy, promiscuity and compensatory mechanisms. As a consequence, a "yeast-like" model where only one Cdk is essential to drive all stages of cell cycle progression is starting to be envisioned for mammalian cells. Moreover, the specific molecular players that drive the cell cycle in mammals seem to be cell-type-specific, and new, non-canonical functions of cyclins and Cdks have been revealed. This review will discuss these new findings and their implications for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16146805     DOI: 10.2741/1871

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  61 in total

1.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

2.  A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Nobuo Ochi; Zhimin Tong; Amit Deorukhkar; Bokyung Sung; Lloyd Kelland; Stephen Jamieson; Rachel Sutherland; Tony Raynham; Mark Charles; Azadeh Bagherzadeh; Azadeh Bagherazadeh; Caroline Foxton; Alexandra Boakes; Muddasar Farooq; Dipen Maru; Parmeswaran Diagaradjane; Yoichi Matsuo; James Sinnett-Smith; Juri Gelovani; Sunil Krishnan; Bharat B Aggarwal; Enrique Rozengurt; Christopher R Ireson; Sushovan Guha
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

3.  miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription.

Authors:  Qipeng Xie; Caiyi Chen; Haiying Li; Jiheng Xu; Lei Wu; Yuan Yu; Shuwei Ren; Hongyan Li; Xiaohui Hua; Huiying Yan; Dapang Rao; Huxiang Zhang; Honglei Jin; Haishan Huang; Chuanshu Huang
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

Review 4.  New combination therapies with cell-cycle agents.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Opin Investig Drugs       Date:  2008-06

Review 5.  Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.

Authors:  Archana Balakrishnan; Arpita Vyas; Kaivalya Deshpande; Dinesh Vyas
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

6.  Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling.

Authors:  Hui Zhou; Liqun Huang; Yu Sun; Basil Rigas
Journal:  Cancer Lett       Date:  2008-09-20       Impact factor: 8.679

7.  c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation.

Authors:  Anup Kumar Singh; Manickavinayaham Swarnalatha; Vijay Kumar
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

8.  Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.

Authors:  Rana P Singh; Komal Raina; Gagan Deep; Daniel Chan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

10.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.